View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
October 28, 2021

Fulgent Genetics introduces lab-developed Covid-19 antibody test

The neutralising antibody test evaluates the risk of severe complications from Covid-19.

Fulgent Genetics has introduced a new lab-developed, at-home neutralising antibody test for Covid-19.

Free Report
img

Navigate your business through the ‘new normal’

COVID-19 continues to dominate headlines the world over. It has already affected our lives forever. The way we work, shop, eat, seek medical advice, and socialize will all be different in the future. Quite how different remains to be seen, but all industries must plan for multiple eventualities.  Faced with an explosion of conflicting information on how to plan and implement successful recovery strategies, decision-makers are in dire need of a single, reliable source of intelligence.   GlobalData’s COVID-19 Executive Briefing gives you access to unparalleled data and insights to successfully navigate the uncertain road to recovery across the world’s largest industries. Understand every aspect of this disruptive theme by delving into: 
  •  COVID-19 infection update, with statistics on the spread, testing by country, as well as the latest data on vaccines and therapeutic developments 
  • Economic impact overview, covering stock market indices, GDP, unemployment rates, policy responses & GlobalData’s economic recovery scorecards 
  • Sector developments, with access to sector insight summaries, cross-sector indices and the leaders and laggards in each industry vertical 
Whatever your company’s imminent strategic plans, the long-lasting impact of COVID-19 must not be overlooked. Find out how to futureproof your business operations – download our report today. 
by GlobalData
Enter your details here to receive your free Report.

The finger prick test measures the neutralising antibody levels that prevent SARS-CoV-2 infection in vaccinated individuals as well as those with a recent infection.

This provides individuals with data regarding their potential resistance levels to Covid-19 and the long-term effectiveness of vaccines.

Fulgent stated that the neutralising antibodies bind to a specific part of a pathogen and have been observed to reduce SARS-CoV-2 viral infection of cells.

The US Food and Drug Administration (FDA)-approved neutralising antibody detection device evaluates the risk of severe complications and monitors long-term immunity from the disease.

Fulgent Genetics chief scientific officer Dr Harry Gao said: “With the launch of our neutralising antibody test, we hope to provide patients and healthcare providers with better data on immunity to Covid-19, whether from the vaccine or a previous infection.

“While we cannot yet conclude whether the presence of neutralising antibodies guarantees immunity against a Covid-19 infection, we hope that this test can help determine immunity levels and the need for vaccine boosters across the population and help to improve our country’s overall response to the virus.”

Fulgent will make the new test available through Picture Genetics, its consumer-initiated platform.

The neutralising antibody test complements the company’s existing RT-PCR and sequencing-based Covid-19 tests.

In August, Fulgent acquired CSI Laboratories to expand its footprint in somatic molecular diagnostics as well as cancer testing.

Through the acquisition, the company plans to enter the somatic genetic testing market, which is estimated to reach $16.8bn by 2030.

Related Companies

Free Report
img

Navigate your business through the ‘new normal’

COVID-19 continues to dominate headlines the world over. It has already affected our lives forever. The way we work, shop, eat, seek medical advice, and socialize will all be different in the future. Quite how different remains to be seen, but all industries must plan for multiple eventualities.  Faced with an explosion of conflicting information on how to plan and implement successful recovery strategies, decision-makers are in dire need of a single, reliable source of intelligence.   GlobalData’s COVID-19 Executive Briefing gives you access to unparalleled data and insights to successfully navigate the uncertain road to recovery across the world’s largest industries. Understand every aspect of this disruptive theme by delving into: 
  •  COVID-19 infection update, with statistics on the spread, testing by country, as well as the latest data on vaccines and therapeutic developments 
  • Economic impact overview, covering stock market indices, GDP, unemployment rates, policy responses & GlobalData’s economic recovery scorecards 
  • Sector developments, with access to sector insight summaries, cross-sector indices and the leaders and laggards in each industry vertical 
Whatever your company’s imminent strategic plans, the long-lasting impact of COVID-19 must not be overlooked. Find out how to futureproof your business operations – download our report today. 
by GlobalData
Enter your details here to receive your free Report.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Medical Device Network